SAN DIEGO, July 13 /PRNewswire-FirstCall/ -- Nanogen, Inc. , developer of advanced diagnostic products, announced today that it has expanded its product portfolio to include MGB Alert(TM) real-time PCR reagents designed to assist laboratories in developing tests that can detect sequences associated with varicella-zoster virus (VZV, also called Human Herpesvirus 3) and Bordetella bacteria. Vaccines exist for both VZV and Bordetella, but the conditions they cause remain endemic for several reasons.
VZV infection causes chicken pox, and its reactivation can trigger the painful neurological disorder shingles. Varicella is an opportunistic pathogen in immuno-compromised individuals and causes severe reactions in children with leukemia and lymphoma. In these cases, rapid diagnosis is needed in order to begin a course of appropriate antiviral therapy. In addition, the proportion of atypical VZV cases has risen, increasing the need for laboratory confirmation of physicians' diagnoses.
Bordetella pertussis and Bordetella parapertussis are the causative organisms for pertussis infection (whooping cough) in humans. Because the current vaccine for Bordetella is only approved for children under seven and does not convey life-long protection, whooping cough has persisted in teens and adults. The vaccine is also not completely effective; breakthrough disease occurs in vaccinated individuals.
"Reagents that can be used in the laboratory-developed tests to detect VZV and Bordetella are the latest addition to Nanogen's MGB Alert Real-Time PCR analyte specific reagents (ASRs)," said Howard Birndorf, Nanogen chairman and CEO. "Diagnosis by Real-Time PCR is possible within a few hours, as compared to traditional culture methods that can take days." PCR tests are also regarded as more accurate and sensitive than currently available direct immunofluorescent assays (DFAs).
All MGB Alert products utilize patented detection chemistry that enables laboratories to develop multiple assays with universal parameters, increasing the efficiency and throughput of clinical testing. The super bases (Super A(TM), Super T(TM), Super G(TM) and Super N(TM)) and MGB technology allow the use of shorter probes with increased sensitivity to mismatches, which have proved essential for detecting short conserved sequences.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip(R) electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen's website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNanogen, Inc.CONTACT: Robert Saltmarsh, Chief Financial Officer, +1-858-410-4600, orSuzanne Clancy, Corporate Communications, +1-858-410-4688,sclancy@nanogen.com, both of Nanogen, Inc.; or Carolyn Hawley of PorterNovelli Life Sciences, Media & Investor Relations, +1-858-527-3484,chawley@pnlifesciences.com, for Nanogen, Inc.
Web site: http://www.nanogen.com/
